COR THERAPEUTICS INC
COR Therapeutics is engaged in the discovery, development, and marketing of novel therapeutic products for treating and preventing acute and chronic cardiovascular diseases. The company’s product portfolio includes Integrilin Injection which is used to treat individuals with cardiovascular diseases. COR Therapeutics also has several product development programs underway to address unmet clinical needs in the management of patients suffering from disorders such as unstable angina, coronary angioplasty, acute myocardial infarction, stroke, and deep vein thrombosis. COR Therapeutics was founded by Lee Douglas and Lewis T. ""Rusty"" Williams in San Francisco, California.
COR THERAPEUTICS INC
Industry:
Health Care Medical Therapeutics
Founded:
1988-01-01
Address:
San Francisco, California, United States
Country:
United States
Status:
Active
Similar Organizations
Ceptaris Therapeutics
Ceptaris Therapeutics is a pharmaceutical company developing therapeutics for symptoms of early-stage mycosis fungoides.
My Next Health
My Next Health builds health applications that provide insights into the prevention and treatment of chronic diseases.
Transmural Systems
Transmural Systems is a medical devices company with a platform of percutaneous structural heart therapies for cardiovascular diseases.
Validus Cellular Therapeutics
Validus Cellular Therapeutics is a developer of therapeutic solutions for treating infectious diseases.
Founder
More informations about "COR Therapeutics Inc"
COR Therapeutics Company Profile 2024: Valuation, Investors
COR Therapeutics has raised $15.9M. Who are COR Therapeutics’s investors? Glynn Capital , InterWest Health Partners , InterWest Partners , Reference Capital Management , and …See details»
COR THERAPEUTICS, INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for COR THERAPEUTICS, INC. of South San Francisco, CA. Get the latest business insights from Dun …See details»
COR Therapeutics Inc - Company Profile and News
COR Therapeutics Inc. discovers and commercializes pharmaceutical products. The Company researches and develops programs that seek to address the critical needs in unstable angina, …See details»
COR Therapeutics Inc acquired by Millennium Pharmaceuticals
COR Therapeutics Inc COR Therapeutics is engaged in the R&D of novel therapeutic products for treating and preventing acute and chronic cardiovascular diseases. Acquiring Organization: …See details»
Cor Therapeutics - Company Profile - Tracxn
Oct 23, 2024 Cor Therapeutics - Glycoprotein IIb/IIIa inhibitors fro the treatment of cardiovascular diseases.. Acquired by Takeda Oncology. Raised funding from 1 investor. Cor …See details»
Cor Therapeutics Company Profile | Management and Employees …
Find contact information for Cor Therapeutics. Learn about their Medical Devices & Equipment, Manufacturing market share, competitors, and Cor Therapeutics's email format.See details»
COR Therapeutics Inc - Crunchbase
COR Therapeutics is engaged in the R&D of novel therapeutic products for treating and preventing acute and chronic cardiovascular diseases. Search Crunchbase Start Free TrialSee details»
Cor Therapeutics Inc - South San Francisco , CA - Company Profile
Cor Therapeutics Inc CLAIM THIS BUSINESS. 256 E GRAND AVE SOUTH SAN FRANCISCO, CA 94080 Get Directions (650) 244-6800. Business Info. Founded 1988; Incorporated DE; …See details»
COR Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials
Explore COR Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 5 news, and 93 literature, Drug:EGR-Xa.See details»
Millennium and COR Therapeutics Agree to Merge, Creating …
Dec 7, 2001 Millennium Pharmaceuticals, Inc. and COR Therapeutics, Inc. today announced that they have signed a definitive agreement for Millennium to acquire COR in a stock-for …See details»
Cor Therapeutics - Overview, News & Similar companies - ZoomInfo
Nov 11, 2020 Who is Cor Therapeutics. X-COR Therapeutics is a Boston-based medical device company creating the first commercially available carbon dioxide removal device that uses …See details»
Millennium and COR Therapeutics agree to merge
Dec 7, 2001 Millennium Pharmaceuticals, Inc. and COR Therapeutics, Inc. have signed a definitive agreement for Millennium to acquire COR in a stock- for-stock exchange valued at …See details»
Cor Therapeutics, Inc. · 256 East Grand Avenue, South San
COR THERAPEUTICS, INC. (Entity #178561) is a business entity in registered with the Business Division of West Virginia Secretary of State (SOS). The organization type is C | Corporation. …See details»
COR THERAPEUTICS INC innovation strategy - GoodIP
COR THERAPEUTICS INC has a total of 437 patent applications. Its first patent ever was published in 1989. It filed its patents most often in United States, Australia and WIPO (World …See details»
Kailian, Vaughn M. - The Wall Street Transcript
Dec 14, 1998 VAUGHN M. KAILIAN has served as President, Chief Executive Officer and a Director of COR Therapeutics, Inc. since March 1990. From 1967 to 1990, Mr. Kailian was …See details»
Farn Huei Chan · Karyopharm Therapeutics Inc. · 2280 Opitz
The payment company is Karyopharm Therapeutics Inc.. The payment date is October 6, 2020. OPEN NPI. Providers . Providers; Doctors and Clinicians; Facilities . Dialysis Facilities; …See details»
Pivotal Therapeutics Inc Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Pivotal Therapeutics Inc of Woodbridge, ON. Get the latest business insights from Dun & Bradstreet.See details»
Perspective Therapeutics, Inc. Market and Competitive Intelligence ...
The average salary for Market and Competitive Intelligence Director at companies like Perspective Therapeutics, Inc. in the United States is $193,000 as of July 29, 2024, but the …See details»
AAR WOODBRIDGE IMAGING CENTER NPI 1356507412 Radiology
Jul 29, 2008 The provider is registered as an organization and their NPI record was last updated 16 years ago. Aar Woodbridge Imaging Center operates as a multi-specialty business group …See details»
Keros Therapeutics Announces Global License Agreement with …
4 days ago Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to …See details»